29th Jun 2018 15:30
LONDON (Alliance News) - FTSE 100-listed pharmaceutical giant AstraZeneca PLC said Friday that it received a positive opinion for its Bydureon Bcise device for the treatment of type-2 diabetes from a European Medicines Agency committee.
The Committee for Medicinal Products for Human Use recommended the inclusion of the device as a new formulation within the marketing authorisation for Bydureon.
The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled pen device aiming to help improve glycaemic control in adults with type-2 diabetes, the company said.
AstraZeneca shares were trading 1.1% higher at 5,280.00 pence each.
Related Shares:
Astrazeneca